Fingerprint
Dive into the research topics of 'The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn, Peter Hillmen, Marco Montillo, Zsolt Nagy, Árpád Illés, Gabriel Etienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Zoltán Gasztonyi, Fritz Offner, Scott Lunin, Francesco Bosch, Matthew S. Davids, Nicole Lamanna, Ulrich Jaeger, Paolo Ghia, Florence Cymbalista, Craig A. Portell, Alan P. Skarbnik
Research output: Contribution to journal › Article › peer-review
219
Scopus
citations